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Pre-clinical safety evaluationThe worldwide incidence of rabies and high rates of therapy failure, despite availability of effective
vaccines indicate the need for timely and improved prophylactic approaches. DNA vaccination based
on optimized formulation of lysosome-targeted glycoprotein of the rabies virus provides potential plat-
form for preventing and controlling rabies. As per the pre-clinical requirements, listed in guidelines of
Schedule Y, FDA and that of The European Agency for evaluation of Medicinal Products; we evaluated
the acute (single dose – 14 days) using three dosing levels, that is, the therapeutic (1), average (5)
and high dose (10) intramuscular toxicity in the rodent model Swiss Albino mice. Furthermore, the
chronic intramuscular toxicity (repeated dose – 43 days with another 14 days for satellite groups) was
investigated using broad dosing levels ranging from low (7), mid (14) to high (28) in Wistar rats.
A range of parameters including physical, physiological, clinical, immunological, hematological along
with histopathology proﬁles of target organs was monitored to assess the impact of vaccination. There
were no observational adverse effects despite high dose administration of the DNA vaccine formulation.
Thus, this study indicates the safety of next generation of vaccines as well as highlights their potential
application.
 2014 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Human rabies is a signiﬁcant public health concern with
approximately 55,000 deaths estimated by the World Health
Organization (WHO) every year [1]. The Indian scenario is grave
with about 36% of the world’s rabies deaths, most of those when
children come into contact with infected dogs [2]. Though Rabies
virus causes a fatal infectious disease, effective protection may
be achieved with immediate administration of rabies immuno-
globulin (RIG) followed by rabies vaccination. WHO also recom-
mends pre-exposure prophylaxis for high risk group like
veterinarians and animal handlers. However, their availability,
requirement of multiple boosters and high cost often leads to
failure of therapy. Also, the lack of knowledge on the appropriatetreatment of bite wounds contributes towards high incidence of
fatal rabies. Dimaano et al. examined the largest cohort of rabies
patients reported and observed the majority of patients were from
lower socioeconomic groups who lacked knowledge, resources, or
both, which compromised their access to appropriate medical care
[3]. Development of alternative counter-measures, preferably a
single dose of more immunogenic and cost effective rabies vaccine
along with awareness on apt treatment post-exposure, is highly
desirable under the current scenario. A preventative vaccine used
for the immunization of children, especially those in high incidence
countries, would be expected to lower fatality rates.
The advancement of recombinant DNA technology has given
way to several new vaccination strategies, notably DNA vaccina-
tion. Several DNA vaccine candidates are currently under develop-
mental phase. The challenge of preclinical development is to
evaluate their safety, pharmacologic, metabolic, and toxicological
properties. This also calls for development of standard regulatory
guidelines for assessing the candidates. We previously reported
the development of a DNA vaccine formulation based on
lysosome-targeted glycoprotein along with Emulsigen-D, which
conferred complete protection on pre-exposure prophylaxis and
post-exposure efﬁcacy analysis [4,5]. This vaccine formulation is
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thus, averts the various side-effects associated with conventional
rabies vaccines. As a pre-requisite for conducting animal and
human clinical trials, the present study was undertaken to evaluate
the pre-clinical toxicology proﬁle, that is, acute and chronic toxic-
ity test of DNA vaccine formulation, in rodent species based on the
Schedule Y guidelines [6].
Materials and methods
As per the regulatory guidelines, the study was designed for
acute and chronic toxicity tests using different dose levels in Swiss
Albino mice and Wistar rats, respectively. The study was used to
evaluate physical, physiological, clinical, haematological and histo-
pathological parameters.
Materials
Test formulations
Rabies DNA vaccine (RDV) was prepared using GMP compliant
facilities at School of Biotechnology, JNU. Emulsigen-D (MVP Labo-
ratories, Inc., Omaha, NE, USA) was used as an adjuvant for RDV.
Test dose
For 1 single dose, 125 lg RDV was mixed with adjuvant at 20%
and volume was made up to 200 ll in 1 PBS. Various dose groups
for acute toxicity were low dose (LD) group containing 125 lg (1)
RDV, mid dose group (MD) containing 625 lg (5) RDV and high
dose (HD) group containing 1250 lg (10), prepared in a desired
volume of PBS, decided according to number of animals in each
group. The vaccine control (VC) group was immunized with 1
PBS and the adjuvant control (AC) group was immunized with
20% adjuvant made in 1 PBS.
Various dose groups for repeated dose toxicity were low dose
(LD) group containing 875 lg (7) RDV, Mid dose (MD) group con-
taining 1750 lg (14) RDV and high dose (HD) group containing
3500 lg (28), prepared in a desired volume of PBS, decided
according to number of animals in each group. 1 PBS was admin-
istered to the vaccine control (VC) group and Emulsigen-D with
PBS was administered to the adjuvant control (AC) group. Three
additional groups were vaccine control satellite (VCS), adjuvant
control satellite (ACS) and high dose satellite (HDS) groups, which
were administered the same dose as their respective non-satellite
groups but were observed for an additional 14 days.
Test species
For acute dose toxicity studies, Swiss Albino mice (Mus muscu-
lus) aged between 4–6 weeks, males weighing between 24–28 g
and females weighing between 20–22 g were obtained from
National Centre for Laboratory Animal Sciences, NIN, Hyderabad,
India. For repeated dose toxicity, 6 weeks old Wistar rats (Rattus
norvegicus) with males weighing 170–190 g and females weighing
135–150 g were also procured from NIN, Hyderabad, India. The
animals were maintained in animal holding facility in BSL3 labora-
tory (School of Biotechnology, Jawaharlal Nehru University, Delhi,
India) at temperature 21–25 C and relative humidity of 55–60%.
12-hourly cycle was set and conventional pelleted diet purchased
from commercial supplier was provided ad libitum to animals
along with reverse osmosis grade pure drinking water. For Wistar
rats, corn cob was used as the bedding material.
Methods
Test details
All tests were done according to Schedule Y guidelines, Ministry
of Health and Family Welfare, Government of India. All experimen-tal procedures were approved by Institutional Animal Ethics Com-
mittee, JNU.
Acute dose toxicity study
Male and female Swiss Albino mice were acclimatized for
7 days in animal holding facility in BSL3 laboratory, following
which they were randomized and allocated to various groups.
Ten mice (5 males and 5 females) of LD, MD and HD groups were
administered a single low dose, single mid dose, and single high
dose, intramuscularly respectively on day 0 with a dose volume
of 100 ll. The adjuvant along with PBS was administrated to the
AC group. Only PBS was administered to the VC group. All the mice
were observed for 14 days for the test item related toxic signs and
symptoms, body weight and mortality.
Repeated dose toxicity study
Male and female Wistar rats were acclimatized for 7 days in
animal holding facility in BSL3 laboratory, following which they
were randomized and 5 male and 5 female rats were allocated to
various groups. All the animals were dosed on the intended dosing
schedule i.e., day 0, day 21 and day 42, intramuscularly with a dose
volume of 300 ll. All the animals in the study were observed for
43 days, except the satellite groups which were further observed
for additional 14 days. The animals were observed for clinical signs
of toxicity, mortality, change in body weight, feed consumption,
changes in hematological and biochemical parameters. Gross nec-
ropsy and histopathology of vital organs was also carried out to
rule out any vaccine induced organ toxicity.
Study parameters
Clinical signs of toxicity. In both acute and repeated dose toxicity
tests, various general clinical signs, food and water intake, general
behaviour and mortality were observed daily. Body weight was
observed every alternate day for acute dose toxicity study and
weekly for repeated dose toxicity study.
Hematological parameters. In repeated dose toxicity tests, hemato-
logical parameters like total leukocyte count (TLC), differential leu-
kocyte count (DLC), red blood cell (RBC) count, haemoglobin (Hb),
haematocrit (HCT), mean corpuscular volume (MCV), mean cor-
puscular haemoglobin (MCH), mean corpuscular haemoglobin con-
centration (MCHC), platelet count, packed cell volume (PCV) were
determined in blood samples drawn into tubes containing EDTA at
various time points, as indicated in the test details and analysed on
an automated blood cell counter.
Blood biochemical parameters. In repeated dose toxicity tests, all
the mice from each group were bled from retro-orbital plexus at
the end-point of study and sera were prepared by standard proce-
dure. Liver function tests (AST, ALT, ALP) and renal function tests
were done. Plasma glucose, albumin, globulin, calcium, triglycer-
ides, sodium, potassium, chloride, calcium, phosphorus and total
bilirubin were estimated using automated chemistry analyzer.
Gross necropsy and histopathology. In acute dose toxicity test, all
the mice were sacriﬁced on day 14 after completion of experimen-
tal period, while in repeated dose toxicity study, all the study ani-
mals were sacriﬁced after completion of 43 days and after
additional 14 days for the satellite group animals. An incision
was made ventrally on each animal’s body to access all vital organs
and gross examination of the organs and tissues (viz, brain, adre-
nal, heart, testes/ovaries, epididymis/uterus, kidneys, liver, lungs,
spleen, spinal cord, trachea, thyroid, thymus, stomach, duodenum,
jejunum, colon, thigh muscle, lymph node, urinary bladder, pros-
tate and seminal vesicles) were done. Absolute weights of these
organs were recorded on electronic weighing balance (Sartorius)
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weight)  100} were calculated. In repeated dose toxicity study,
the collected organs were preserved in 10% buffered formalin. All
the preserved tissues were processed for parafﬁn embedding. 4–
6 lm thick sections were cut and stained using hematoxylin and
eosin dye and subjected to microscopic evaluation. Histopathology
of the ﬁxed organs and tissues from all animals of both sexes
belonging to the VC, AC and HD groups along with thigh muscle
from LD, MD, VCS, ACS and HDS groups were processed for parafﬁn
embedding. All deviations from normal histology were recorded
and compared with corresponding controls.
Statistical analysis. The data on variations, if any, of body weights,
feed consumption, hematology, biochemistry and organ weights
was analysed among treated and control groups by ANOVA using
GraphPad Prism software (Version 4.01).
Results
Acute dose toxicity study
Body weight of all the mice of all groups was taken every alter-
nate day for 14 days. It was observed that there was no signiﬁcant
statistical difference in body weight gain in test groups as com-
pared to the control groups (Fig. 1). No major change in feed con-
sumption was observed for any of the groups. All the animals in allDays
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Fig. 1. Body weight of male (A) and female (B) Swiss Albino mice in acute dose toxicit
14 days. Their mean body weight has been represented in the ﬁgure.
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Fig. 2. Body weight of male (A) and female (B) Wistar rats in repeated dose toxicity test. W
groups was recorded for another 2 weeks. The ﬁgure represents the mean body weightgroups appeared normal throughout the experimental period. No
mortality was observed in any group. All the animals were sacri-
ﬁced and gross examination of all vital organs was performed for
all the animals at termination of the study (data not shown). There
was no evidence of organ toxicity in any animal.Repeated dose toxicity study
Body weight
Both male and female Wistar rats of all groups (LD, MD, HD, VC
and AC groups) exhibited a progressive increase in body weight
during the entire course of the study. A similar increase in body
weight was also observed in the animals of VCS, ACS and HDS
groups. Weekly mean body weight of all animals till six weeks
for LD, MD, HD, VC and AC groups and till 8 weeks for VCS, ACS
and HDS groups is shown in Fig. 2. The difference in body weight
gain of test groups and their respective control groups was statis-
tically non-signiﬁcant, indicating no vaccine speciﬁc changes.Feed consumption
Weekly feed consumption in male and female rats of treated
and control groups showed a similar pattern throughout the study
and the same pattern of feed consumption was also observed in
satellite group animals (data not shown).Days
0 2 4 6 8 10 12 14 16
18
20
22
24
26
28
Low dose group
Mid dose group
High dose group
vaccine control
Adjuvant control
B
y test. Body weight of all the mice of all groups was taken every alternate day for
No. of weeks
0 2 4 6 8 10
W
ei
gh
t (
 in
 g
ra
m
s)
 
120
140
160
180
200
220
240
260
Low dose group
Mid dose group
High dose group
Vaccine control
Adjuvant control
Vaccine control satellite
Adjuvant control satellite
High dose satellite
B
eekly body weight of all animals was monitored for 6 weeks, while that of satellite
of all the groups.
Ta
bl
e
1a
H
em
at
ol
og
ic
al
pr
oﬁ
le
of
m
al
e
W
is
ta
r
ra
ts
in
re
pe
at
ed
do
se
to
xi
ci
ty
te
st
.V
al
ue
s
ar
e
in
M
ea
n
±
SE
M
,⁄
in
di
ca
te
s
si
gn
iﬁ
ca
nt
in
cr
ea
se
or
de
cr
ea
se
in
va
lu
e
w
it
h
p
<
0.
05
,⁄
⁄
si
gn
iﬁ
ca
nt
in
cr
ea
se
or
de
cr
ea
se
in
va
lu
e
w
it
h
p
<
0.
01
an
d
#
in
di
ca
te
s
co
m
pa
ri
so
n
w
it
h
ad
ju
va
nt
co
nt
ro
l
gr
ou
p.
Pa
ra
m
et
er
s
Lo
w
do
se
M
id
do
se
H
ig
h
do
se
V
ac
ci
n
e
co
n
tr
ol
A
dj
u
va
n
t
co
n
tr
ol
V
ac
ci
n
e
co
n
tr
ol
sa
te
ll
it
e
A
dj
u
va
n
t
co
n
tr
ol
sa
te
ll
it
e
H
ig
h
do
se
sa
te
ll
it
e
H
ae
m
og
lo
bi
n
(g
/d
l)
14
.6
7
±
0.
17
15
.0
0
±
0.
12
14
.8
8
±
0.
14
14
.6
8
±
0.
14
15
.2
0
±
0.
23
15
.5
0
±
0.
28
14
.6
7
±
0.
31
14
.9
2
±
0.
35
TL
C
(/
cu
m
m
)
25
00
0
±
19
32
.0
1⁄
#
25
90
0
±
26
50
.2
8⁄
⁄#
21
43
3.
33
±
76
2.
31
19
90
0
±
14
32
.9
5
17
23
3.
33
±
10
69
.1
6
16
15
0
±
12
63
.2
6
17
98
3.
33
±
15
21
.0
6
14
18
3.
33
±
91
3.
39
N
eu
tr
op
h
il
(%
)
60
.1
7
±
2.
55
⁄⁄
#
62
.1
7
±
2.
32
⁄⁄
#
61
.3
3
±
1.
74
⁄#
21
.3
3
±
3.
33
38
.5
0
±
5.
59
⁄⁄
16
.3
3
±
1.
20
24
.1
7
±
2.
87
⁄
22
.6
7
±
1.
45
Ly
m
ph
oc
yt
e
(%
)
36
.5
0
±
2.
35
⁄⁄
#
35
.1
7
±
2.
51
⁄⁄
#
35
.8
3
±
1.
78
⁄#
74
.5
0
±
3.
32
56
.5
0
±
5.
18
⁄⁄
80
.6
7
±
1.
33
71
.6
7
±
2.
81
⁄
74
.0
0
±
1.
44
Eo
si
n
op
h
il
(%
)
1.
50
±
0.
34
⁄#
0.
67
±
0.
21
⁄#
0.
83
±
0.
17
⁄#
1.
67
±
0.
21
2.
83
±
0.
54
0.
83
±
0.
31
1.
33
±
0.
49
1.
17
±
0.
17
M
on
oc
yt
e
(%
)
1.
83
±
0.
17
2.
00
±
0.
45
2.
00
±
0.
26
2.
50
±
0.
34
2.
17
±
0.
17
2.
17
±
0.
31
2.
83
±
0.
31
2.
17
±
0.
48
B
as
op
h
il
(%
)
0.
00
±
0.
00
0.
00
±
0.
00
0.
00
±
0.
00
0.
00
±
0.
00
0.
00
±
0.
00
0.
00
±
0.
00
0.
00
±
0.
00
0.
00
±
0.
00
R
B
C
(m
il
li
on
s/
cu
m
m
)
8.
53
±
0.
19
8.
59
±
0.
15
8.
66
±
0.
08
8.
17
±
0.
11
8.
65
±
0.
22
9.
15
±
0.
26
8.
72
±
0.
17
8.
46
±
0.
36
M
C
V
(ﬂ
)
54
.7
2
±
0.
71
54
.6
5
±
0.
57
54
.5
7
±
0.
30
55
.9
8
±
0.
88
54
.3
0
±
1.
41
53
.3
2
±
0.
48
52
.4
5
±
0.
36
52
.6
7
±
0.
76
M
C
H
C
(g
/d
l)
31
.4
5
±
0.
31
31
.9
8
±
0.
29
31
.5
3
±
0.
16
32
.1
3
±
0.
24
29
.3
8
±
2.
47
31
.8
2
±
0.
36
32
.0
5
±
0.
30
32
.6
3
±
0.
50
PC
(
10
00
/l
l)
10
27
.3
3
±
40
.0
3
96
3.
90
±
19
2.
92
99
9.
83
±
31
.4
2
94
1.
50
±
47
.0
4
10
61
.3
3
±
35
.8
7
11
33
.5
0
±
61
.8
1
11
88
.5
0
±
32
.9
3
10
91
.3
3
±
85
.2
5
PC
V
(%
)
47
.8
5
±
0.
81
47
.8
5
±
0.
81
46
.6
5
±
0.
67
46
.9
3
±
0.
38
47
.2
2
±
0.
55
48
.7
7
±
1.
30
45
.7
7
±
1.
14
45
.1
3
±
1.
64
76 R. Garg et al. / Trials in Vaccinology 3 (2014) 73–80Hematological investigations
Evaluation of hematological parameters in male rats revealed
statistically signiﬁcant increase in TLC in LD and MD groups as
compared to VC and AC group. In neutrophils, signiﬁcant percent-
age increase was observed in LD, MD, HD, AC and ACS groups as
compared to VC group. In contrast, a signiﬁcant decrease in lym-
phocyte percentage was observed in all these groups, as compared
to the VC group. LD, MD and HD groups also exhibited signiﬁcant
decrease in percentage of eosinophils, as compared to VC as well
as AC groups (Table 1a). Since, HDS group did not show any prom-
inent variation; these changes in blood proﬁle cannot be attributed
to RDV. In female rats, signiﬁcant enhancement of neutrophil count
was observed for LD, MD, HD and AC groups as compared to VC
group. The lymphocyte population exhibited signiﬁcant decrease
in all these groups as compared to the VC group. Minor changes
were seen in RBC count and MCHC in LD, MD and HD groups as
compared to VC group. In PCV, signiﬁcant differences were noticed
in LD as compared to VC group (Table 1b). The above variations in
RBC count, MCHC, PC, and PCV and haemoglobin were considered
incidental ﬁndings due to absence of dose dependent trend and
lack of biological correlation.
Biochemical investigations
Biochemical parameters in male rats revealed statistical
changes in SGPT (in AC group), SGOT (in MD group), calcium (in
LD and MD groups), triglyceride (in MD group), total cholesterol
(in LD, MD and HD groups), potassium (LD and MD), phosphorous
(AC, LD, MD and HD) and blood glucose (in MD and HD) levels
when compared to Vaccine Control groups. In male ACS group, sig-
niﬁcant changes in SGOT levels were seen when compared with
VCS, whereas in HDS group, statistically signiﬁcant changes in
SGOT levels were observed when compared with ACS group
(Table 2a). Likewise in female rats, signiﬁcant changes in ALP (in
LD group), phosphorus (in HD group), triglyceride (in LD group),
calcium (in LD, MD and HD group), albumin (AC, LD, MD and HD
group), sodium (LD and HD), chloride (LD & HD), blood glucose
in (MD and HD), were observed in comparison to VC and AC
groups. HDS group showed change in sodium levels when com-
pared with ACS group (Table 2b). These may be incidental ﬂuctua-
tions in view of absence of dose dependent correlation.
Organ weights
Absolute organ weights of all the treated groups including satel-
lite groups were comparable with their respective control groups
and the differences were found to be statistically non-signiﬁcant
in both male and female Wistar rats (Tables 3a and 3b).
Gross pathology
External gross pathological examination of all organs did not
reveal any abnormalities in both the treated and the control
groups. Internal gross pathological examination of LD animals
showed hard muscle mass at the site of injection in all male and
female mice. Same observation was made in 5/6 males, 4/6 females
of MD group and all males as well as females of HD group. The VC
group did not show any abnormality, while the AC group showed
abnormality in one male and all female rats.
Histopathological evaluation
Histopathological examination revealed severe acute inﬂamma-
tion in muscle and soft tissues of thigh muscle at site of injection in
several animals in the treated as well as AC groups. Some of these
also showed abscess formation and granulomas at the injection
site. Similar features were also seen in the injection site biopsies
from LD and MD groups. The injection site biopsies from the ACS
and HDS group showed persistence of the inﬂammatory cell inﬁl-
tration. The VC and control VCS groups’ biopsies did not show
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R. Garg et al. / Trials in Vaccinology 3 (2014) 73–80 77any inﬂammation at the injection site. No other abnormality was
seen in any other organ from any of the groups (data not shown).Discussion
Rabies continues to pose serious threat to humans and animals
worldwide. Around 55,000 deaths are reported every year in Asia
and Africa only [7]. In U.S., the number of human deaths from
rabies has declined from more than 100 annually at the turn of
the century to one or two per year in the 1990’s [8]. New, better
and an affordable vaccine for pre- as well as post-exposure prophy-
laxis along with proper management remains the only solution to
combat the disease’s toll. DNA vaccines provide a cheap and efﬁ-
cient strategy proven in various animal models like BALB/c mice
[5], rabbits [9], dogs, cats [10], horses [11] and cattle [10]. pDNA
preparation adjuvanted with snake cardiotoxin gave 100% protec-
tion against challenge in mice model and ﬁve times higher anti-
bodies than without adjuvant [13]. A novel cost-effective
combination vaccine (CRV) containing rabies DNA vaccine and
inactivated rabies virus vaccine imparted full protection against
rabies challenge in mice and higher antibody titer in cattle [12].
100% survival against CVS challenge was seen in cats immunized
intradermally with glycoprotein G based DNA vaccine [14].
We previously reported the development of a rabies DNA
vaccine, consisting of the lysosome-targeted glycoprotein of rabies
virus expressed in eukaryotic plasmid pDNAVACC. The construct,
when evaluated in BALB/c mice was found to impart partial protec-
tion against lethal challenge [4]. The RDV was optimized for
dosage, administration route as well as the adjuvant usage, such
that, the optimized DNA vaccine formulation elicited high level
of rabies virus neutralizing antibodies (RVNAs) and conferred com-
plete protection in both pre-exposure prophylaxis and post-expo-
sure efﬁcacy analysis [5]. This vaccine formulation is ﬁrst of its
kind in India, as it is free of any viral component and thus, averts
the various side-effects associated with conventional rabies vac-
cines. As a pre-requisite for conducting animal and human clinical
trials, the present study was undertaken to evaluate the pre-clini-
cal toxicology proﬁle, that is, acute and chronic toxicity test of DNA
vaccine formulation, in rodent species based on the Schedule Y
guidelines [6].
In view of developing this novel vaccine formulation, as a safe,
potent and cost-effective anti-rabies vaccine, safety and pre-clini-
cal toxicity parameters need to be evaluated in animal species.
Such studies should only be conducted in relevant species, that
is, the ones that demonstrate pharmacological effects. The species
usually used for conducting vaccine associated toxicology studies
on rodents (mice or rats) or rabbits [15]. In the present study, we
carried out systemic acute as well as repeated dose toxicity studies,
according to Schedule Y guidelines of Ministry of Health and Fam-
ily Welfare, in Drugs and Cosmetics (IInd Amendment) Rules, 2005
[16], International guidelines by FDA [17,18] as well as guidelines
of The European Agency for evaluation of Medicinal Products [19].
Here, rodent species – Swiss Albinomice andWistar rats were used
as model animals for acute and repeated dose toxicity studies,
respectively. Swiss Albino mice has rapidly gained acceptance as
choice of animal for conducting such studies based on afﬁnity
and rapid higher antibody response during the efﬁcacy trials. Sev-
eral studies have demonstrated the potential of Wistar rats in tox-
icity trials.
The Pharmacia & Upjohn Company, Michigan proposed a three
tier system for drug’s preclinical evaluation [20]. This includes Tier
I for assaying the immune toxic effects. The next level, the Tier II
parameters are investigated if any abnormality or deviation is
observed for Tier I parameters. This involves organ-speciﬁc toxicity
studies. The Tier III is a highly speciﬁc study, which probes
Table 2a
Clinical chemistry parameters of male Wistar rats in repeated dose toxicity test. Values are in Mean ± SEM, ⁄ indicates signiﬁcant increase or decrease in value with p < 0.05, ⁄⁄
signiﬁcant increase or decrease in value with p < 0.01 and # indicates comparison with adjuvant control group.
Parameters Low dose Mid dose High dose Vaccine
control
Adjuvant
control
Vaccine control
satellite
Adjuvant control
satellite
High dose
satellite
SGPT (IU/L) 45.17 ± 3.47 42.17 ± 3.64 46.50 ± 4.77 53.50 ± 5.39 38.67 ± 1.94⁄ 52.67 ± 2.23 48.17 ± 2.95 45.00 ± 3.66
SGOT (IU/L) 175.67 ± 14.23 143.33 ± 10.65⁄ 161.50 ± 14.72 201.67 ± 12.04 165.50 ± 10.80 139.83 ± 6.96 170.17 ± 6.47⁄ 146.33 ± 7.36⁄#
ALP (U/L) 232.67 ± 22.61 210.33 ± 9.30 195.83 ± 16.15 196.83 ± 30.18 213.33 ± 17.07 287.50 ± 25.13 331.83 ± 34.58 302.33 ± 40.24
Phosphorus
(mg/dl)
7.94 ± 0.16⁄⁄ 7.80 ± 0.39⁄⁄ 8.02 ± 0.26⁄⁄ 6.48 ± 0.14 7.63 ± 0.36⁄ 6.43 ± 0.17 6.78 ± 0.11 7.00 ± 0.34
Total bilirubin
(mg/dl)
0.86 ± 0.01 0.83 ± 0.08 0.85 ± 0.05 0.73 ± 0.06 0.87 ± 0.05 0.61 ± 0.07 0.67 ± 0.09 0.64 ± 0.05
BUN (mg/dl) 20.67 ± 1.12 18.50 ± 0.92 19.83 ± 0.91 20.17 ± 0.48 18.50 ± 0.96 17.50 ± 1.20 20.00 ± 1.21 19.17 ± 0.79
Creatinine (mg/
dl)
0.61 ± 0.01 0.60 ± 0.01 0.59 ± 0.02 0.58 ± 0.01 0.57 ± 0.01 0.46 ± 0.02 0.49 ± 0.01 0.49 ± 0.01
Triglyceride
(mg/dl)
118.50 ± 12.27 155.00 ± 18.21⁄# 108.83 ± 10.02 119 ± 18.10 103.17 ± 8.04 88.33 ± 22.43 83.17 ± 2.44 92.67 ± 14.91
Cholesterol total
(mg/dl)
63.00 ± 4.27⁄ 73.33 ± 3.24⁄⁄# 63.17 ± 2.81⁄ 49.33 ± 2.87 57.33 ± 3.46 56.17 ± 3.38 57.67 ± 2.59 58.17 ± 4.40
Calcium (mg/dl) 8.23 ± 0.07⁄⁄# 8.20 ± 0.10⁄⁄# 8.57 ± 0.11 8.95 ± 0.13 8.88 ± 0.25 9.70 ± 0.13 9.70 ± 0.13 9.63 ± 0.03
Albumin (g/dl) 3.95 ± 0.05 3.97 ± 0.06 3.97 ± 0.07 4.13 ± 0.06 3.95 ± 0.03 3.92 ± 0.11 3.90 ± 0.09 3.98 ± 0.09
Total Protein (g/
dl)
7.03 ± 0.13 7.45 ± 0.15 6.98 ± 0.15 7.28 ± 0.11 7.12 ± 0.20 6.98 ± 0.07 7.07 ± 0.12 6.88 ± 0.11
Globulin (g/dl) 3.08 ± 0.10 3.48 ± 0.14 3.02 ± 0.11 3.15 ± 0.16 3.17 ± 0.18 3.07 ± 0.13 3.17 ± 0.14 2.90 ± 0.13
Sodium (mEq/L) 158.50 ± 0.92 156.17 ± 1.47 156.42 ± 1.36 154.78 ± 1.02 157.93 ± 1.31 139.82 ± 0.55 138.27 ± 0.16 138.78 ± 0.72
Potassium
(mEq/L)
6.21 ± 0.14⁄⁄ 5.89 ± 0.08 6.41 ± 0.10⁄⁄# 5.75 ± 0.09 5.96 ± 0.04 5.02 ± 0.12 5.37 ± 0.05 5.29 ± 0.12
Chloride (mEq/
L)
113.47 ± 1.1 116.47 ± 1.97 114.90 ± 1.43 118.07 ± 1.13 117.00 ± 0.92 104.55 ± 0.66 104.52 ± 0.43 105.57 ± 0.69
Table 2b
Clinical chemistry parameters of female Wistar rats in repeated dose toxicity test. Values are in Mean ± SEM, ⁄ indicates signiﬁcant increase or decrease in value with p < 0.05, ⁄⁄
signiﬁcant increase or decrease in value with p < 0.01 and # indicates comparison with adjuvant control group.
Parameters Low dose Mid dose High dose Vaccine
control
Adjuvant
control
Vaccine control
satellite
Adjuvant control
satellite
High dose
satellite
SGPT (IU/L) 46.67 ± 3.30 54.83 ± 1.96 49.33 ± 3.63 50 ± 3.97 46.33 ± 1.84 45.67 ± 2.76 52.33 ± 7.20 56.00 ± 5.09
SGOT (IU/L) 136.83 ± 6.45 150.67 ± 11.01 145.00 ± 17.76 149.5 ± 9.08 158.83 ± 9.72 146.33 ± 9.85 159.17 ± 5.02 154.67 ± 5.96
ALP (U/L) 318.50 ± 22.11⁄⁄ 268.50 ± 30.28 266.17 ± 37.84 176.67 ± 26.11 207.67 ± 33.35 247.67 ± 26.03 298.50 ± 58.43 300.00 ± 51.84
Phosphorus
(mg/dl)
6.13 ± 0.56 6.83 ± 0.76 7.61 ± 0.39⁄ 5.29 ± 0.33 5.70 ± 0.37 5.33 ± 0.29 6.05 ± 0.37 5.66 ± 0.18
Total bilirubin
(mg/dl)
0.72 ± 0.02 0.60 ± 0.08 0.79 ± 0.06 0.59 ± 0.06 0.64 ± 0.06 0.60 ± 0.03 0.60 ± 0.02 0.61 ± 0.04
BUN (mg/dl) 20.17 ± 1.47 19.67 ± 0.92 19.67 ± 1.52 207.67 ± 33.35 17.67 ± 0.76 22.00 ± 0.89 25.00 ± 0.89 23.83 ± 1.96
Creatinine (mg/
dl)
0.60 ± 0.02 0.60 ± 0.01 0.61 ± 0.02 0.57 ± 0.02 0.62 ± 0.02 0.58 ± 0.02 0.57 ± 0.01 0.58 ± 0.02
Triglyceride
(mg/dl)
128.00 ± 13.31⁄⁄# 80.83 ± 7.99 82.17 ± 5.80 87.33 ± 19.16 54.50 ± 4.35 74.83 ± 7.21 64.00 ± 7.78 83.33 ± 12.43
Total cholesterol
(mg/dl)
74.50 ± 6.23 78.50 ± 5.19 68.83 ± 7.35 71.83 ± 7.31 85.50 ± 5.07 73.17 ± 3.16 74.83 ± 4.02 73.83 ± 4.09
Calcium (mg/dl) 8.32 ± 0.14⁄ 8.00 ± 0.20⁄⁄# 8.07 ± 0.03⁄⁄# 8.78 ± 0.05 8.72 ± 0.08 9.63 ± 0.13 9.60 ± 0.15 9.77 ± 0.11
Albumin (g/dl) 4.18 ± 0.09⁄⁄# 4.43 ± 0.06⁄⁄ 4.57 ± 0.05⁄⁄ 4.93 ± 0.07 4.62 ± 0.06⁄ 4.10 ± 0.10 4.07 ± 0.10 4.10 ± 0.05
Total protein (g/
dl)
7.55 ± 0.19 7.65 ± 0.11 8.07 ± 0.24 8.03 ± 0.14 8.02 ± 0.17 6.88 ± 0.13 7.05 ± 0.11 6.90 ± 0.12
Globulin (g/dl) 3.37 ± 0.17 3.22 ± 0.10 3.50 ± 0.24 3.10 ± 0.20 3.40 ± 0.15 2.78 ± 0.12 2.98 ± 0.12 2.80 ± 0.12
Sodium (mEq/L) 143.03 ± 1.01⁄# 147.25 ± 2.55 141.48 ± 1.34⁄⁄# 148.72 ± 2.32 150.47 ± 1.07 144.07 ± 1.88 141.17 ± 1.00 145.82 ± 1.11⁄#
Potassium
(mEq/L)
5.03 ± 0.09 5.33 ± 0.16 5.26 ± 0.14 5.09 ± 0.06 5.18 ± 0.10 5.03 ± 0.08 5.29 ± 0.14 5.34 ± 0.11
Chloride (mEq/
L)
107.78 ± 0.34⁄ 109.55 ± 1.79 107.03 ± 1.12⁄ 112.40 ± 1.60 110.78 ± 0.84 105.48 ± 1.51 107.18 ± 1.47 104.83 ± 0.51
Blood glucose
(mg/dl)
106.5 ± 8.87 89.17 ± 3.70 94.83 ± 3.20 106.5 ± 8.87 89.17 ± 3.70 89.00 ± 4.14 74.33 ± 7.99 78.33 ± 6.03
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establishment of the mechanisms of toxicity. The present investi-
gation was carried out in agreement with Tier I and II assays. Type
I immunotoxicological parameters involved hematological and
serological histopathological tests, while the Type II examination
was based on histopathological analysis of internal organs for
immune reactivity or suppression on the basis of FDA guidelines
[21].
In acute dose toxicity study, for the entire test period (14 days),
all the experimental animals did not show any clinical sign of tox-
icity, even at the highest concentration (10 dose). Male andfemale mice showed comparable body weight gain and feed con-
sumption with that of controls throughout the study period. Gross
examination of the mice organs revealed no abnormalities at the
termination of the study. These results are in agreement with the
studies done earlier by Kumar et al. for their vaccines DRV and
CRV [22]. In repeated dose toxicity study also, the routine param-
eters like behaviour pattern, feeding pattern, and body weights of
various groups did not show any statistically signiﬁcant alteration,
which can be attributed to the treatment. Though, hematological
and biochemical analysis carried out at the end of the dosing
period showed certain signiﬁcant ﬂuctuations, however, due to
Table 3a
Mean organ weights of vital organs of male Wistar rats in repeated dose toxicity test. Values are in Mean ± SEM for each group.
Parameters Mean organ weight (g)
Low dose Mid dose High dose Vaccine
control
Adjuvant
control
Vaccine control
satellite
Adjuvant control
satellite
High dose
satellite
Mean fasting body
weight
305.37 ± 22.57 305.57 ± 16.58 296.42 ± 23.99 321.55 ± 10.65 297 ± 13.46 347.6 ± 18.83 345.77 ± 16.15 337.33 ± 13.18
Brain 1.75 ± 0.06 1.72 ± 0.05 1.75 ± 0.09 1.79 ± 0.11 1.73 ± 0.07 1.78 ± 0.03 1.76 ± 0.05 1.78 ± 0.05
Heart 1.30 ± 0.09 1.23 ± 0.06 1.14 ± 0.05 1.09 ± 0.06 1.13 ± 0.08 1.27 ± 0.04 1.27 ± 0.07 1.23 ± 0.04
Adrenal 0.05 ± 0.01 0.05 ± 0.01 0.05 ± 0.01 0.05 ± 0.01 0.04 ± 0.004 0.05 ± 0.01 0.05 ± 0.01 0.05 ± 0.005
Testes 2.77 ± 0.11 2.84 ± 0.10 2.70 ± 0.09 2.75 ± 0.12 2.86 ± 0.07 2.96 ± 0.09 2.95 ± 0.10 2.93 ± 0.06
Epididymis 1.07 ± 0.08 1.07 ± 0.08 1.01 ± 0.09 1.11 ± 0.08 1.12 ± 0.08 1.17 ± 0.04 1.13 ± 0.02 1.18 ± 0.07
Kidneys 2.80 ± 0.17 2.72 ± 0.14 2.63 ± 0.30 2.55 ± 0.30 2.50 ± 0.13 2.90 ± 0.16 2.81 ± 0.12 2.67 ± 0.15
Liver 14.05 ± 1.06 13.65 ± 0.64 12.84 ± 1.49 13.54 ± 0.70 14.02 ± 1.91 13.52 ± 0.92 12.49 ± 0.58 11.31 ± 0.62
Thymus 0.36 ± 0.03 0.31 ± 0.02 0.30 ± 0.04 0.33 ± 0.03 0.22 ± 0.04 0.24 ± 0.03 0.20 ± 0.01 0.21 ± 0.01
Spleen 0.96 ± 0.14 0.90 ± 0.08 0.69 ± 0.06 1.01 ± 0.14 0.66 ± 0.05 0.84 ± 0.09 0.82 ± 0.08 0.73 ± 0.06
Lungs 2.25 ± 0.15 2.20 ± 0.13 1.94 ± 0.13 2.21 ± 0.08 1.97 ± 0.21 2.04 ± 0.13 2.31 ± 0.10 2.23 ± 0.19
Table 3b
Mean organ weights of vital organs of female Wistar rats in repeated dose toxicity test. Values are in Mean ± SEM for each group.
Parameters Mean organ weight (g)
Low dose Mid dose High dose Vaccine
control
Adjuvant
control
Vaccine control
satellite
Adjuvant control
satellite
High dose
satellite
Mean fasting body
weight
206.60 ± 6.77 208.08 ± 8.87 203.85 ± 9.70 206.28 ± 14.45 207.88 ± 7.95 217.48 ± 4.10 206.63 ± 9.48 220.10 ± 12.35
Brain 1.68 ± 0.05 1.61 ± 0.04 1.66 ± 0.06 1.68 ± 0.03 1.60 ± 0.03 1.66 ± 0.04 1.68 ± 0.08 1.65 ± 0.05
Heart 0.96 ± 0.07 0.98 ± 0.06 0.88 ± 0.05 0.80 ± 0.04 0.87 ± 0.04 0.73 ± 0.02 0.84 ± 0.04 0.89 ± 0.04
Adrenal 0.06 ± 0.01 0.07 ± 0.003 0.06 ± 0.004 0.06 ± 0.003 0.05 ± 0.01 0.05 ± 0.01 0.06 ± 0.01 0.06 ± 0.003
Ovaries 0.14 ± 0.005 0.13 ± 0.01 0.12 ± 0.006 0.11 ± 0.01 0.12 ± 0.004 0.12 ± 0.004 0.12 ± 0.01 0.14 ± 0.01
Uterus 0.49 ± 0.03 0.44 ± 0.04 0.37 ± 0.02 0.43 ± 0.05 0.46 ± 0.03 0.48 ± 0.05 0.45 ± 0.07 0.49 ± 0.03
Kidneys 1.95 ± 0.08 1.92 ± 0.09 1.77 ± 0.09 1.68 ± 0.08 1.76 ± 0.05 1.58 ± 0.06 1.67 ± 0.10 1.76 ± 0.02
Liver 9.04 ± 0.42 9.49 ± 0.47 8.88 ± 0.23 8.27 ± 0.42 8.56 ± 0.35 7.20 ± 0.25 7.06 ± 0.43 7.76 ± 0.23
Thymus 0.25 ± 0.01 0.30 ± 0.05 0.23 ± 0.03 0.25 ± 0.05 0.26 ± 0.04 0.31 ± 0.04 0.22 ± 0.04 0.33 ± 0.03
Spleen 0.60 ± 0.04 0.58 ± 0.04 0.58 ± 0.06 0.05 ± 0.03 0.54 ± 0.04 0.53 ± 0.05 0.54 ± 0.04 0.61 ± 0.05
Lungs 1.79 ± 0.08 1.71 ± 0.12 1.50 ± 0.07 1.57 ± 0.12 1.53 ± 0.06 1.55 ± 0.05 1.80 ± 0.11 1.85 ± 0.11
R. Garg et al. / Trials in Vaccinology 3 (2014) 73–80 79lack of dose dependent pattern; these changes were not considered
to be associated with vaccine administration. The gross pathologi-
cal examination of site of injection revealed hard muscle mass as
well as severe acute inﬂammation in all cases except vaccine con-
trol and vaccine control satellite groups. Some cases also showed
abscess formation and granulomas. Since, these changes were
detected in all the groups except vaccine control groups, it can
be concluded that these changes are due to RDV. Based on above
results, it may be concluded that, RDV is non-toxic to Swiss Albino
mice at a single dose of 5 mg/kg (10 therapeutic dose) when
administered intramuscularly. The ‘‘No Observed Adverse Effect
Level’’ (NOAEL) of RDV when administered three times repeatedly
by intramuscular route in both the sexes of Wistar rats was found
to be 14 mg/kg (4 therapeutic dose) of body weight.
This study is conducted in accordance with guidelines proposed
for Institutional Biosafety committees by Department of Biotech-
nology, India [23] for investigating safety proﬁle of in-house devel-
oped products. The results obtained suggest that the novel RDV
formulation does not have immunotoxicity and can be considered
safe. To further establish its potential, we intend to carry out sys-
temic toxicity studies in non-rodent model. Also, a broad range
of parameters like male and female fertility study, female repro-
duction and developmental toxicity studies, teratogenicity, local
toxicity, hypersensitivity, carcinogenicity and genotoxicity will be
studied, as proposed in the Schedule Y guidelines.Conclusions
The present study indicates the preclinical safety and non-tox-
icity of the novel rabies DNA vaccine formulation. The pre-clinicaldata generated here has not only encouraged us to take this
vaccine formulation ahead for clinical trials, but also, added on
the knowledge pool on DNA vaccines, further strengthening their
immense potential.Contributions
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